Soluble Receptors for Tumor Necrosis Factor and Neopterin as Parameters of Cell-Mediated Immune Activation

References

• W. Fiers. Tumor necrosis factor: Characterization at the molecular, cellular and in vivo level. FEBS Lett, 285, 199–212, (1991).
   PubMed Web of Science ®Google Scholar
• P. Brouckaert, C. Libert, B. Everaerdt, N. Takahashi, A. Cauwels, W. Fiers. Tumor necrosis factor, its receptors and the connection with interleukin 1 and interleukin 6. Immunobiology, 187, 317–29, (1993).
   PubMed Web of Science ®Google Scholar
• T.J. Schall, M. Lewis, R.J. Roller, A. Lee, G.C. Rice, G.H.W. Wong, T. Gatanaga, G.A. Granger, R. Lentz, FI. Raab, W.J. Rohr, D.V. Goeddel. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell, 61, 361–70, (1990).
   PubMed Web of Science ®Google Scholar
• L.A. Tartaliga, D.V. Goeddel. Two TNF receptors. Immunol Today, 13, 151–3, (1992).
   PubMedGoogle Scholar
• I. Olsson, T. Gatanaga, U. Gullberg, M. Lantz, G.A. Granger. Tumor necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Netw, 4, 169–80, (1993).
   PubMed Web of Science ®Google Scholar
• N. Itoh, S. Yonehara, A. Ishii, M. Yonehara, S.I. Mizushima, M. Sameshima, A. Hase, Y. Seto, S. Nagata. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66, 233–43, (1991).
   PubMed Web of Science ®Google Scholar
• D. Camerini, G. Walz, W.A.M. Loenen, J. Borst, B. Seed. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol, 147, 3165–9, (1991).
   PubMed Web of Science ®Google Scholar
• M. Lewis, L.A. Tartaglia, A. Lee, G.L. Bennett, G.C. Rice, G.H.W. Wong, EY. Chen, D.V. Goeddel. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA, 88, 2830–34, (1991).
   PubMed Web of Science ®Google Scholar
• H. Engelmann, H. Holtmann, C. Brakebusch, Y.S. Avni, I. Sarova, Y. Nophary, E. Hadas, O. Leitner, D. Wallach. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem, 265, 497–504, (1990).
   Web of Science ®Google Scholar
• H. Loetscher, Y.C.E. Pan, H.W. Lahm, R. Gentz, M. Brockhaus, H. Tabuchi, W. Lesslauer. Molecular cloning epression of thehuman 55 kD tumor necrosis factor receptor. Cell, 61, 351–9, (1990).
   PubMed Web of Science ®Google Scholar
• C.A. Smith, T. Davis, D. Anderson, L. Salom, M.P. Backmann, C.A. Smith, R. Jerzy, S.R. Dower, D. Cosman, G. Goodwin. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science, 248, 1019–23, (1990).
   PubMed Web of Science ®Google Scholar
• H.P. Hohmann, R. Remy, M. Brockhaus and A.P.G.M. van Loon. Two different cell types have different major receptors for human tumor necrosis factor (TNF-α). J Biol Chem, 264, 14927–34, (1989).
   PubMed Web of Science ®Google Scholar
• M. Brockhaus, H.J. Schönfeld, W. SchlÓger, W. Hunziker, W. Lesslauer, H. Loetscher. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA, 87, 3127–31, (1990).
   PubMed Web of Science ®Google Scholar
• G. Gehr, R. Gentz, M. Brockhaus, H. Loetscher, W. Lesslauer. Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. J Immunol, 149, 911–7, (1992).
   PubMed Web of Science ®Google Scholar
• B.J. Erikstein, E.B. Smeland, H.R. Blomhoff, S. Funderud, R. Prydz, W. Lesslauer, T. Espevik. Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood lymphocytes. Eur J Immunol, 21, 1033–7, (1991).
   PubMed Web of Science ®Google Scholar
• R. Pandita, E. Pocsik, B.B. Aggarwal. Interferon-γ induces cell surface expression for both types of tumor necrosis factor receptors. FEBS Lett, 12, 87–90, (1992).
   Google Scholar
• I. Olsson, M. Lantz, E. Nilsson, C. Peetre, H. Thysell, A. Gmbb, G. Adolf. Isolation and characterization of a tumour necrosis factor binding protein from urine. Eur J Haematol, 42, 270–5, (1989).
   PubMed Web of Science ®Google Scholar
• T. Rohno, M.T. Brewer, S.L. Baker, P.E. Schwartz, M.W. Ring, R.R. Hale, C.H. Squires, R.C. Thompson, J.L. Vannice. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA, 87, 8331–5, (1990).
   PubMed Web of Science ®Google Scholar
• Y. Nophar, O. Remper, C. Brakebusch, H. Englemann, R. Zwang, D. Aderka, H. Holtmann, D. Wallach. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The c-DNA for the type I TNF-R, cloned using aminoacid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J, 9, 3269–78, (1990).
   Google Scholar
• M. Lantz, F. Björnberg, I. Olsson, J. Richter. Adherence of neutrophils induces release of soluble tumor necrosisfactor receptor forms. J Immunol, 152, 1362–9, (1994).
   PubMed Web of Science ®Google Scholar
• P.D. Crowe, T.L. VanArsdale, R.G. Goodwin, C.F. Ware. Specific induction of 80kD tumor necrosis factor receptor shedding in T lymphocytes involves the cytopolasmic domain and phosphorylation. J Immunol, 151, 6882–90, (1993).
   PubMed Web of Science ®Google Scholar
• J.F.M. Leeuwenberg, T.M.A.A. Jeunhomme, W.A. Buurman. Slow release of soluble TNF receptors by monocytes in vitro. J Immunol, 152, 4036–43, (1994).
   PubMed Web of Science ®Google Scholar
• M.J. Bargetzi, M. Lantz, C.G. Smit, F.M. Torti, I. Olsson, S.P. Eisenberg, H.F. Starnes. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. Cancer Res, 53, 4010–3 (1993).
   PubMed Web of Science ®Google Scholar
• R. Landmann, U. Keilholz, C. Scheibenbogen, H. Brockhaus, H. Gallati, H. Denz, M. Bargetzi, C. Ludwig. Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha. Cancer Immunol Immunother, 38, 113–8, (1994).
   PubMed Web of Science ®Google Scholar
• H. Tilg, E. Trehu, M.B. Atkins, C.A. Dinarello, J.W. Mier. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood, 83, 113–8, (1994).
   PubMed Web of Science ®Google Scholar
• D. Aderka, H. Engelmann, V. Hornik, Y. Skornick, Y. Levo, D. Wallach, G. Kushtai. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res, 51, 5602–7 (1991).
   PubMed Web of Science ®Google Scholar
• W. Digel, F, Porzsolt, M. Schmid, F. Herrman, W. Lesslauer, M. Brockhaus. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest, 89, 1690–3, (1992).
   PubMed Web of Science ®Google Scholar
• Y. Abe, Y. Watanabe, S. Kimura. The role of tumor necrosis factor receptors in cell signalling and the significance of soluble forms levels in the serum. Jpn J Surg, 24, 197–202, (1994).
   Google Scholar
• D. Aderka, H. Engelmann, Y. Maor, C. Brakebusch, D. Wallach. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med, 175, 323–9, (1992).
   PubMed Web of Science ®Google Scholar
• D. Fuchs, A. Hausen, G. Reibnegger, E.R. Werner, M.P. Dierich, H. Wachter. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today, 9, 150–5, (1988).
   PubMedGoogle Scholar
• H. Wachter, D. Fuchs, A. Hausen, G. Reibnegger, E.R. Werner. Neopterin as marker for activation of cellular immunity: Immunologic basis and clinical application. Adv Clin Chem 27, 81–141, (1989).
   PubMed Web of Science ®Google Scholar
• D. Fuchs, G. Weiss, G. Reibnegger, H. Wachter. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit Rev Clin Lab Sci, 29, 307–341, (1992).
   PubMed Web of Science ®Google Scholar
• D. Fuchs, G. Weiss, H. Wachter. Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol, 101, 1–6, (1993).
   PubMed Web of Science ®Google Scholar
• G. Reibnegger, C. Aichberger, D. Fuchs, A. Hausen, M. Spielberger, E.R. Werner, R. Margreiter, H. Wachter. Posttransplant neopterin excretion in renal allograft recipients—A reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival. Transplantation, 52, 58–63, (1991).
   PubMed Web of Science ®Google Scholar
• D. Fuchs, M. Malkowsky, G. Reibnegger, E.R. Werner, G. Forni, H. Wachter. Endogenous release of interferon gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. Immunol Lett, 23, 103–8, (1989/90).
   PubMed Web of Science ®Google Scholar
• S. Romagnani. Induction of Th1 and Th2 responses: a key role for the ‘natural’ immune response? Immunol Today, 13, 379–81, (1992).
   PubMedGoogle Scholar
• A. O'Garra, K. Murphy. Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol, 6, 458–66, (1994).
   PubMed Web of Science ®Google Scholar
• E. Maggi, P. Parronchi, P. Manetti. Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human TH1 and TH2 clones. J Immunol, 148, 2142–7, (1992).
   PubMed Web of Science ®Google Scholar
• P. Salgame, J.S. Abrams, C. Clayberger, H. Goldstein, J. Convit, R.L. Modlin. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science, 254, 279–82, (1991).
   PubMed Web of Science ®Google Scholar
• A. Sher, R.T. Gazzinelli, I.P. Oswal, M. Clerici, M. Kullberg, E.J. Pearle, J.A. Berzofsky, T.R. Mosmann S.L. James, H.C. Morse. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev, 127, 183–204, (1992)
   PubMed Web of Science ®Google Scholar
• D. Fuchs, T.J. Spira, A. Hausen, G. Reibnegger, E.R. Werner, G. Werner-Felmayer, H. Wachter: Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem, 35, 1746–9, (1989).
   PubMed Web of Science ®Google Scholar
• J.L. Fahey, M.D. Jeremy, M.G. Taylor, R. Detels, B. Hofmann, R. Melmed, P. Nishanian, J.V. Giorgi. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med, 18, 166–172, (1990).
   Google Scholar
• A. KrÓmer, S.Z. Wiktor, D. Fuchs, S. Milstein, M.H. Gail, F.J. Yellin, R.J. Biggar, H. Wachter, S. Kaufman, W.A. Blattner, J.J. Goedert. Neopterin: A predictive marker of acquired immune deficiency syndrome in human immunodeficiency virus infection. J Acquir Immune Defic Syndr, 2, 291–6, (1989).
   PubMed Web of Science ®Google Scholar
• G. Reibnegger, D. Fuchs, L.C. Fuith, A. Hausen, E.R. Werner, G. Werner-Felmayer, H. Wachter. Neopterin as a marker for activated cell-mediated immunity: Application in malignant disease. Cancer Detect Prevent, 15, 483–490, (1991).
   PubMedGoogle Scholar
• I. Engelberts, A. Moeller, G.J.M. Schoen, C.J. Van der Linde, W.A. Buurman. Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res, 10, 69–76, (1991).
   PubMedGoogle Scholar
• A. Diez-Ruiz, G.P. Tilz, R. Zangerle, G. Baier-Bitterlich, H. Wachter, D. Fuchs. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol, 54, 1–8, (1995).
   PubMed Web of Science ®Google Scholar
• M.Y. Samsonov, G.P. Tilz, O. Egorova, G. Reibnegger, R.M. Balabanova, E.L. Nassonova, V.A. Nassonova, H. Wachter, D. Fuchs. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus, 4, 29–32, (1995).
   PubMed Web of Science ®Google Scholar
• A. Diez-Ruiz, G. P. Tilz, F. Gutierrez-Gea, B. Gil-Extremera, C. Murr, H. Wachter. Neopterin and soluble tumor necrosis factor receptor type I in alcoholic cirrhosis. Hepatology, 21, 976–8, (1995).
   PubMed Web of Science ®Google Scholar
• P. Aukrust, N.B. Liabakk, F. Müller, E. Lien, T. Espevik, S.S. Froland. Serum levels of tumor necrosis factor-α (TNF-α) and soluble TNF receptors in human immunodeficiency virus type I infection. Correlations to clinical immunologic, and virologic parameters. J Infect Dis, 169, 420–4, (1994).
   Google Scholar
• R. Zangerle, H. Gallati, M. Sarcletti, H. Wachter, D. Fuchs. Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection. Immunol Lett, 41, 229–34, (1994).
   PubMed Web of Science ®Google Scholar
• G.P. Tilz, W. Domej, A. Diez-Ruiz, G. Weiss, R. Brezinschek, H.P. Brezinschek, E. Hüttl, H. Pristautz, H. Wachter, D. Fuchs. Increased immune activation during and after physical exercise. Immunobiol, 188, 194–202, (1993).
   PubMed Web of Science ®Google Scholar
• R. Zangerle, M. Sarcletti, H. Gallati, G. Reibnegger, H. Wachter, D. Fuchs. Correlation of body mass index with urinary neopterin in individuals infected with human immunodeficiency virus. Int Arch Allergy Immunol, 104, 150–4, (1994).
   PubMed Web of Science ®Google Scholar
• M.H.A. Bemelmans, D.J. Gouma, W.A. Buurman. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol, 150, 2007–17, (1993).
   PubMed Web of Science ®Google Scholar
• H. Denz, B. Orth, G. Weiss, H. Gallati, R. Herrmann, P. Huber, H. Wachter, D. Fuchs. Serum soluble tumour necrosis factor receptor 55 is increased in patients with haematological neoplasias and is associated with immune activation and weight loss. Eur J Cancer, 29A, 2232–5, (1993).
   PubMed Web of Science ®Google Scholar
• F.T. Cordingley, A. Bianchi, A.V. Hoffbrand, J.E. Reittie, H.E. Heslop, A. Vyakaram, M. Turner, A. Maeger, M.K. Brenner. Tumor necrosis factor as an autocrine tumor growth factor for chronic B cell malignancies. Lancet 1, 969–71, (1988).
   PubMed Web of Science ®Google Scholar
• J.D. Hasday, E.M. Shah, A.P. Lieberman. Macrophage tumor necrosis factor-alpha release is induced by contact with some tumors. J Immunol, 45, 371–9, (1990).
   Google Scholar
• P.H. Black. Shedding from normal and cancer cell surface. N Engl J Med, 303, 1415–6, (1980).
   PubMed Web of Science ®Google Scholar
• E.A. Grosen, G.A. Granger, M. Gatanaga, E.K. Ininns, C. Hwang, P. Disaia, M. Berman, A. Manetta, D. Emma, T. Gatanaga. Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy. Gynecol Oncol, 50, 68–77, (1993).
   PubMed Web of Science ®Google Scholar
• A. Belldegrun, W. Pierce, D. Sayah, J. de Kernion, D. Wallach, D. Aderka, R.A. Figlin. Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with interleukin-2-based immunotherapy. J Immunother, 13, 175–80, (1993).
   Web of Science ®Google Scholar
• F. Langkopf, J. Atzpodien. Soluble tumor necrosis factor receptors as prognostic factors in cancer patients. Lancet, 344, 57–8, (1994).
   PubMed Web of Science ®Google Scholar
• G. Poli, A. Kinter, J.S. Justement, J.H. Kehrl, P. Bressler, S. Stanley, A.S. Fauci. Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA, 87, 782–5, (1990).
   PubMed Web of Science ®Google Scholar
• T.M. Folks, K.A. Clouse, J. Justement, A. Rabson, E. Duh, J.A. Kehrl, A.S. Fauci. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA, 86, 2365–8, (1989).
   PubMed Web of Science ®Google Scholar
• J.W. Mellors, B.P. Griffith, M.A. Ortiz, M.L. Landry, J.L. Ryan. Tumor necrosis factor-alpha/cachectin enhances human immunodeficiency virus type I replication in primary macrophages. J Infect Dis, 163, 78–82, (1991).
   PubMed Web of Science ®Google Scholar
• T. Matsuyama, N. Kobayashi, N. Yamamoto, Editorial review. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS, 5, 1405–17, (1991).
   PubMed Web of Science ®Google Scholar
• A. Vyakarnam, J. McKeating, A. Meager, P.C. Beverly. Tumor necrosis factors (α,β) induced by HIV-1 in peripheral blood mononuclear cells potentiate virus replication. AIDS, 4, 21–7, (1990).
   PubMed Web of Science ®Google Scholar
• S.C. Wright SC, Jewett A, Mitsuyasu R, Bonavida B. Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol, 141, 99–104 (1988).
   PubMed Web of Science ®Google Scholar
• B.J. Dezube, A.B. Pardee, L.A. Beckett, C.M. Ahlers, L. Ecto, J. Allen-Ryon, A. Anisowicz, R. Sager, C.S. Crumpacker. Cytokine dysregulation in AIDS: in vivo overexpression of mRNA of tumor necrosis factor alpha and its correlation with that of the inflammatory cytokine GRO. J Acquir Immune Defic Syndr, 5, 1099–104, (1992).
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Cerami A. The role of cachectin/tumor necrosis factor in AIDS. Cancer Cells, 1, 62–3 (1990).
   Web of Science ®Google Scholar
• J.M. Molina, R. Schindler, R. Ferriani, M. Sakaguchi, E. Vannier. Production of cytokines by peripheral blood monocytes/macrophages infected with human immunodeficiency virus type I (HIV-1). J Infect Dis, 161, 888–93, (1990).
   PubMed Web of Science ®Google Scholar
• M.M. Reddy, S.J. Sorrell, M. Lange, M.H. Grieco. Tumor necrosis factor and HIV p24 antigen levels in serum of HIV-infected populations. J Acquir Immune Defic Syndr, 1, 436–40, (1988).
   PubMed Web of Science ®Google Scholar
• J. Laehdevirta, C.P.J. Maury, A.M. Teppo, H. Repo. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med, 85, 289–91, (1988).
   PubMed Web of Science ®Google Scholar
• M.H. Godfried, T. van der Poll, G.J. Weverling, J.W. Mulder, J. Jensen, S.J. von-Deventer, H.P. Sauerwein. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type I infection. J Infect Dis, 169, 739–45, (1994).
   PubMed Web of Science ®Google Scholar
• R. Zangerle, H. Gallati, M. Sarcletti, G. Weiss, H. Denz, H. Wachter, D. Fuchs. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV infected individuals are associated with immune activation. J Acquir Immune Defic Syndr, 7, 79–85, (1994).
   PubMed Web of Science ®Google Scholar
• R. Zangerle, D. Fuchs, M. Sarcletti, H. Gallati, G. Reibnegger, H. Wachter, M.P. Dierich, J. Möst. Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4 + lymphocytes in HIV infection. Clin Immunol Immunopathol, 72, 328–34, (1994).
   PubMedGoogle Scholar
• G. Werner-Felmayer, E.R. Werner, D. Fuchs, A. Hausen, G. Reibnegger, H. Wachter. Tumor necrosis factor-alpha and lipopolysaccharide enhance intefer-on-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe Seyler, 370, 1063–69, (1989).
   PubMed Web of Science ®Google Scholar
• P. Biswas, G. Poli, A.L. Kinter, J.S. Justement, S.K. Stanley, W.J. Maury, P. Bressler, J.M. Orenstein, A.S. Fauci. Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells. J Exp Med, 176, 739–50, (1992).
   PubMed Web of Science ®Google Scholar
• O.M.Z. Howard, K.A. Clouse, C. Smith, R.G. Goodwin, W.L. Farrar. Soluble tumor necrosis factor receptor: inhibition of human immunodeficiency virus activation. Proc Natl Acad Sci USA, 90, 2335–9, (1993).
   PubMed Web of Science ®Google Scholar
• P. Portegies, M.H. Godfried, R. Q. Hintzen. Low levels of specific T cell activation marker CD27 accompanied by elevated levels of non-specific immune activation in the cerebrospinal fluid of patients with AIDS dementia complex. J Neuroimmunol, 48, 241–7, (1993).
   PubMed Web of Science ®Google Scholar
• D. Fuchs, F. Chiodi, J. Albert, B. Asjö, L. Hagberg, A. Hausen, G. Norkrans, G. Reibnegger, E.R. Werner, H. Wachter. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS, 3, 285–8, (1989).
   PubMed Web of Science ®Google Scholar
• R. Zangerle, M. Sarcletti, H. Gallati, G. Reibnegger, H. Wachter, D. Fuchs. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr, 7, 1149–56, (1994).
   PubMed Web of Science ®Google Scholar
• D. Fuchs, A. Hausen, G. Reibnegger, E.R. Werner, G. Wemer-Felmayer, M.P. Dierich, H. Wachter. Immune activation and the anaemia associated with chronich inflammatory disorders. Eur J Haematol, 46, 65–70, (1991).
   PubMed Web of Science ®Google Scholar
• A. Waage, A. Halstensen, T. Espevik. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet, 1, 135–7, (1987).
   PubMed Web of Science ®Google Scholar
• E. Girardin, P. Roux-Lombard, G.E. Grau, P. Sutzer, H. Gallati, J.M. Dayer. Imbalance between tumor necrosis factor-alphaand soluble TNF receptor concentrations in severe meningococcaemia. Immunology, 76, 20–3,(1992).
   PubMed Web of Science ®Google Scholar
• M. van Deuren, J. van der Ven-Jongekrijg, P.N.M. Demacker, A.K. Bartelink, R. van Dalen, R.W. Sauerwein, H. Gallati, J.L. Vannice, J.M. van der Meer. Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis, 169, 157–61, (1994).
   PubMed Web of Science ®Google Scholar
• K.J. Tracey, B. Beutler, S. F. Lowry, J. Merryweather, W. Stephen, I. W. Milsark, R. J. Hariri, T. J. Fahey III, A. Zentella, J. D. Albert, G. Tom Shires, A. Cerami. Shock and tissue injury induced by recombinant human cachectin. Science, 234, 470–4, (1986).
   PubMed Web of Science ®Google Scholar
• T. van der Poll, J. Jansen, D. van Leenen, M. van der Mohlen, M. Levi, H. ten-Cate, H. Gallati, J.W. ten-Cate, S.J. van-Deventer. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis, 168, 955–60, (1993).
   PubMed Web of Science ®Google Scholar
• K. M. Mohler, D. S. Torrance, C. A. Smith, R. G. Goodwin, K. E. Stremler, V. P. Fung, H. Madoni, M. B. Widmer. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol, 151, 1548–61, (1993).
   PubMed Web of Science ®Google Scholar
• T. Butler, M. Ho, G. Archarya, M. Tiwari, H. Gallati. Interleukin-6, gamma interferon and tumor necrosis factor receptorsin typhoid fever related to outcome of antimicrobial therapy. Antimicrob Agents Chemother, 37, 2418–21, (1993).
   PubMed Web of Science ®Google Scholar
• M. Keuter, E. Dharmana, M.H. Gasem. Patterns of proinflammatory cytokines and inhibitors during typhoid fever. J Infect Dis, 169, 1306–11, (1994).
   PubMed Web of Science ®Google Scholar
• P. Kern, C.J. Hemmer, H. Gallati, S. Neifer, P. Kremsner, M. Dietrich, F. Porzsolt. Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J Infect Dis, 166, 930–4, (1992).
   PubMed Web of Science ®Google Scholar
• P. Kern, W.V. Kern, P. Kremsner. Soluble tumor necrosis factor receptors in plasmodium vivax malaria. J Infect Dis, 168, 1340–41, (1993).
   PubMed Web of Science ®Google Scholar
• G. Reibnegger, V. Boonpucknavig, D. Fuchs, A. Hausen, E. Schmutzhard, H. Wachter. Urinary neopterin is elevated in patients with malaria. Trans Roy Soc Trop Med Hyg, 78, 545–54, (1984).
   PubMed Web of Science ®Google Scholar
• A.E. Brown, D.A. Herrington, H.K. Webster, D.F. Clyde, M.B. Sztein, J.R. Davis, M.S. Beier, R. Edelman. Urinary neopterin in volunteers experimentally infected with plasmodium falciparum. Trans Roy Soc Trop Med Hyg, 86, 134–6, (1992).
   PubMed Web of Science ®Google Scholar
• M. Feldmann, F.M. Brennan, D. Chantry. Cytokine assays role in evolution of the pathogenesis of autoimmunity. Immunol Rev, 119, 105–23, (1991).
   PubMed Web of Science ®Google Scholar
• M. Linker-Israeli. Cytokines abnormalities in human lupus. Clin Immunol Immunopathol, 63, 10–2, (1992).
   PubMedGoogle Scholar
• D. Aderka, A. Wysenbeek, H. Engelman, A.P. Cope, F. Brennan, Y. Molad, V. Hornik, Y. Levo, R.N. Maini, M. Feldmann, D. Wallach. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systhemic lupus erythematosus. Arthritis Rheum, 36, 1111–20, (1993).
   PubMedGoogle Scholar
• B. Heilig, C. Fiehn, M. Brockhaus, H. Gallati, A. Pezzutto, W. Hunstein. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol, 13, 321–8, (1993).
   PubMed Web of Science ®Google Scholar
• A.P. Cope, D. Aderka, M. Doherty, H. Engelmann, D. Gibbons, A.C. Jones, F.M. Brennan, R.N. Maini, D. Wallach, M. Feldmann. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum, 35, 1160–9, (1992).
   PubMed Web of Science ®Google Scholar
• B. Heilig, M. Wermann, H. Gallati, M. Brockhaus, B. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis. Clin Investig, 70, 22–7, (1992).
   PubMedGoogle Scholar
• P. Roux-Lombard, L. Punzi, F. Hasler, S. Bas, S. Todesco, H. Gallati, P.A. LGueme, J.M. Dayer. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum, 36, 485–9, (1993).
   PubMed Web of Science ®Google Scholar
• G. Reibnegger, D. Egg, D. Fuchs, R. Günther, A. Hausen, E.R. Werner, H. Wachter. Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis. Arthritis Rheum, 29, 1063–70, (1986).
   PubMed Web of Science ®Google Scholar
• N. Tsukada, M. Matsuda, K. Miyagi, N. Yanagisawa. Increased levels of intercellular adhesion molecule 1 (ICAM-1) and soluble tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology, 43, 2679–82, (1993).
   PubMed Web of Science ®Google Scholar
• S. Fredrikson, P. Eneroth, H. Link. Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis. Clin Exp Immunol, 67, 76–81, (1987).
   PubMed Web of Science ®Google Scholar
• R. Latini, M. Bianchi, E. Correale, C.A. Dinarello, G. Fantuzzi, C. Fresco, A.P. Maggioni, M. Mengozzi, S. Romano, L. Shapiro. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol, 23, 1–6, (1994).
   PubMed Web of Science ®Google Scholar
• W.V. Kern, A. Engel, S. Schieffer, O. Prummer, P. Kern. Circulating tumor necrosis alpha (TNF), soluble TNF receptors and interleukin-6 in human subacute bacterial endocarditis. Infect Immun, 61, 5413–6, (1993).
   PubMed Web of Science ®Google Scholar
• M.Y. Samsonov, E.L. Nassonov, H. Wachter, D. Fuchs. Heart diseases and immune system activation. Eur J Intern Med, 4, 267–280, (1994).
   Google Scholar
• M.Y. Samsonov, G.P. Tilz, V.P. Pisklakov, G. Reibnegger, E.L. Nassonova, V.A. Nassonova, H. Wachter, D. Fuchs. Serum-soluble receptors for tumor necrosis factor-α and interleukin-2, and neopterin in acute rheumatic fever. Clin Immunol Immunopathol, 74, 31–34, (1995).
   PubMedGoogle Scholar
• H. Tilg, W. Vogel, C.J. Wiedermann, L. Shapior, M. Herold, G. Judmaier, C.A. Dinarello. Circulating Interleukin-1 and tumor necrosis factor antagonists in liver disease. Hepatology, 18, 1132–8, (1993).
   PubMed Web of Science ®Google Scholar
• T. Andus, V. Gross, A. Holstege, M. Ott, M. Weber, M. David, H. Gallati, W. Gerok, J. Scholmerkh. High concentrations of soluble tumor necrosis factor receptors in ascites. Hepatology, 16, 749–55, (1992).
   PubMed Web of Science ®Google Scholar
• D. Fuchs, A. Hausen, G. Reibnegger, E.R. Werner, P. Dittrich, H. Wachter. Neopterin levels in long term hemodialysis. Clin Nephrol, 30, 220–4,(1988).
   PubMed Web of Science ®Google Scholar
• G. Halwachs, Q. Tiran, E.C. Reisinger, R. Zach, K. Sabin, B. Folsch, H. Lanzer, H. Holzer, Wilders-Truschnig M. Serum levels of the soluble receptor for tumor necrosis factor in patients with renal disease. Clin Investig, 72, 473–6, (1994).
   PubMedGoogle Scholar
• R.C. Chasty, W.R. Lamb, H. Gallati, T.E. Roberts, P.E. Brenchley, J.A. Yin. Serum cytokine levels in patients undergoing bone marrow transplantation. Bone Marrow Transplantation, 12, 331–6, (1993).
   PubMed Web of Science ®Google Scholar
• T. Kraus, A. Mehrabi, J.C. Arnold, M. Wermann, E. Klar, G. Ott, C. Herfarth, B. Heilig. Evaluation of soluble tumor necrosis factor receptors after orthotopic liver transplantation. Transplant Proc, 24, 2539–41, (1992).
   PubMed Web of Science ®Google Scholar
• J.C. Arnold, B. Heilig, B. Kallinowsky, G. Otto, B. Kommerell, L. Theilmann. Soluble tumor necrosis factor receptors in patients with recurrent hepatitis C virus infection after liver transplantation. Clin Investig, 72, 470–7, (1994).
   PubMedGoogle Scholar
• A. Hausen, C. Aichberger, A. Königsrainer, G. Weiss, R. Margreiter, H. Wachter. Biliary and urinary neopterin concentrations in monitoring liver-allograft recipients. Clin Chem, 39, 45–7, (1993).
   PubMed Web of Science ®Google Scholar
• R. Debets, F.J. Savelkoul. Cytokine antagonists and their potential therapeutic use. Immunol Today, 15, 455–58, (1994).
   PubMedGoogle Scholar
• M. Haak-Frendscho, S.A. Marsters, J. Mordenti, S. Brady, N.A. Gillett, S.A. Chen, A. Ashkenazi. Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody. J Immunol, 152, 1347–53, (1994).
   Google Scholar
• G. Weiss, D. Fuchs, A. Hausen, G. Reibnegger, E. R. Werner, G. Werner-Felmayer, E. Semenitz, M. P. Dierich, H. Wachter. Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett, 321, 89–92, (1993).
   PubMed Web of Science ®Google Scholar
• D. Fuchs, A. Gruber, F. Überall, H. Wachter. Oxidative stress and apoptosis. Immunol Today, 15, 496, (1994).
   PubMedGoogle Scholar
• F. Überall, G. Wemer-Felmayer, C. Schubert, H. H. Grunicke, H. Wachter, D. Fuchs. Neopterin derivatives together with cyclic guanosine monophosphat induce c-fos gene expression. FEBS Lett, 352, 11–4, (1994).
   PubMed Web of Science ®Google Scholar
• G. Baier-Bitterlich, D. Fuchs, C. Murr, G. Reibnegger, G. Wemer-Felmayer, R. Sgonc, G. Böck, M. P. Dierich, H. Wachter. Effect of neopterin and 7,8-dihydroneopterin on tumor necrosis factor-α induced programm cell death. FEBS Lett, 364, 234–8, (1995).
   PubMed Web of Science ®Google Scholar
• L.S. Rusten, S.E.W. Jacobsen. Tumor necrosis factor (TNF)-α directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood, 85, 989–96, (1995).
   PubMed Web of Science ®Google Scholar
• D. Fuchs, A. Hausen, G. Reibnegger, E.R. Werner, G. Wemer-Felmayer, M.P. Dierich, H. Wachter. Immune activation and the anaemia associated with chronic inflammatory disorders. Eur J Heamatol, 46, 65–70, (1991).
   PubMed Web of Science ®Google Scholar
• G. Weiss, H. Wachter, D. Fuchs. Linkage of cell-mediated immunity to iron metabolism. Immunol Today, 16, 495–500, (1995).
   PubMedGoogle Scholar
• W. Schobersberger, W. Jelkmann, J. Fandrey, S. Frede, H. Wachter, D. Fuchs. Neopterin-induced suppression of erythropoietin production in vitro. Pteridines, 6, 12–16, (1995).
   Web of Science ®Google Scholar